Peptide-based Anxiolytics: Molecular Aspects of Heptapeptide Selank Biological Activity
Tatiana V Vyunova, Lioudmila Andreeva, Konstantin Shevchenko, Nikolay Myasoedov · 2018 · Curr Mol Pharmacol. PMID 30255741
What does this source report?
The authors examine GABA-binding modulation as a possible mechanistic explanation.
- Population and setting
- Radioligand binding and isolated brain-cell membrane assays
- Evidence type
- In vitro
- Preparation
- Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted
- Source language
- See original publication; indexed English metadata
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Receptor-binding results are laboratory evidence, not proof of clinical efficacy.
- Interactions in an assay do not establish safe combinations with other drugs.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: Tatiana V Vyunova, Lioudmila Andreeva, Konstantin Shevchenko, Nikolay Myasoedov. Peptide-based Anxiolytics: Molecular Aspects of Heptapeptide Selank Biological Activity Curr Mol Pharmacol. PMID 30255741 2018.
Molekul research summary: https://molekul.io/research/ss-30255741. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry